In patients with breast cancers or lung cancers harboring the wild-type p53, the decreased expression of P53RRA was significantly related to a poor prognosis (Mao et al., 2018), and p53 is considered as one of the most promising molecular targets for cancer therapy (Chasov et al., 2020). The gene discussed is TP53; the disease is lung cancer.